In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.
about
AntigenDB: an immunoinformatics database of pathogen antigensCombination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infectionImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesRegulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and VaccinationApoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunityToward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptorsSrc homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responsesCancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma.CCR4 is a determinant of melanoma brain metastasisThe immunology of tuberculosis: from bench to bedside.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionStructural Analysis of Chemokine Receptor-Ligand Interactions.Programmed death 1 and cytokine inducible SH2-containing protein dependent expansion of regulatory T cells upon stimulation With Mycobacterium tuberculosis.Effect of Different Adjuvants on Protection and Side-Effects Induced by Helicobacter suis Whole-Cell Lysate Vaccination.Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR.CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses.Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.NK1.1+ cells and IL-22 regulate vaccine-induced protective immunity against challenge with Mycobacterium tuberculosis.Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironmentNaloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responsesSurveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications.Towards the knowledge-based design of universal influenza epitope ensemble vaccines.Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy.Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance.Manipulation of regulatory T-cell function by immunomodulators: a boon or a curse?Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.Engineering dendritic cells to enhance cancer immunotherapy.Pharmacological modulation of chemokine receptor function.Targeting regulatory T cells.Systematic identification of small molecule adjuvants.Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Harnessing the regulators to enhance viral vaccine efficacy.The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them.Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models.Cytokines and Chemokines in Mycobacterium tuberculosis Infection.Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin.Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies.
P2860
Q24644600-C9F2CE16-AA3E-48AB-B758-9E4A041497B8Q26748624-940BF728-F182-4943-87C8-47528783D335Q26798402-DC3AE81B-1453-41A7-98D8-D14464D36A05Q28081492-0C51E9ED-E297-4E9E-9366-3A0BDA96AFCBQ28385358-7E91CDE6-5D55-4ED5-9343-F43100DF2A9DQ28472202-DBD34AC6-35FD-4CD6-BA22-802C49EB952EQ28487315-E0BA379E-DB09-44D4-A080-2E18E6DA2831Q33753714-317591BB-F279-43FE-B422-D6EEA9FBE8BEQ33761639-94881F58-6BE4-4E54-BA67-A9FDA35A90B0Q33777367-F92E90B1-53A8-4A81-8FA6-9CE6F5DC41E9Q34175958-C621C407-F2CF-4931-9370-FF7BE4E5D544Q34550666-99457F59-0FDE-4DC7-8F09-9811BCC0E3A4Q34754932-DA17FBB8-CEE7-4E82-AA91-BB60A2502C1BQ35675819-52530106-21FB-4B8F-9FB7-C6CE20A6C7ECQ35759485-29CFA3CE-A31D-4E56-BC7D-E7D275E21607Q36050578-8057C2AE-0A02-4F55-8C15-99AF06C067F5Q36057441-A6742D83-B149-4028-92D0-F66CA5411F19Q36083904-3344706C-7732-4768-9F07-9BE3886B879FQ36555077-B562EB7E-6960-4E4C-977A-A7FFD36A83E7Q36922528-D3B6FD6C-B5DE-43AF-8044-F2A8A7B8422DQ36972226-11416BB9-631A-49D3-BC31-75F11C05551CQ37164125-33B313B7-E883-4ECD-8788-165132379429Q37365222-B82B8A8D-C46A-4C88-964E-80E8EC275763Q37468057-10EB1B7E-00EC-46EB-B7F6-6DFEBF088932Q37659828-EAE95C2B-6DA9-44BB-85F2-BE1EF084878CQ37756417-A912F9C5-CF66-4CD8-8F59-FA22F0CA4DFEQ37788679-000DB727-8463-473A-BC2C-AE66F5DF4387Q37862064-C2E0B165-B3E8-46CF-BED0-4F18314DE925Q37893687-8A53F136-C457-4876-9449-F1AF1E3DB87AQ37983467-92463F51-3ECD-4F34-9041-5FBF48EF5F05Q38020881-0CA8A2E1-9829-4B5F-845B-68F807B6701BQ38406177-1B35D3F8-1820-4033-B8C9-B102367099EAQ38647661-7597A7C6-7C0D-4892-9C02-A4E31CC2D6CFQ38734257-3B629211-E63D-47F6-8DF8-DF268DBC6772Q38877137-81E4018F-4F2E-40DF-8501-3E0BD8AB7AA3Q38976083-586CCDB2-88C9-4ADB-8185-C46C8554D6D4Q38986062-6B7D12D8-EBB9-4C9D-A0DE-FD03DB7C689EQ40011543-A073C3A8-73E3-48AD-8C50-5D3B1FEBA136Q41061299-D7615D46-8A32-48A2-9945-8B5D1CF8D920Q41728362-0E713A92-617E-453C-9161-88F0395E1DE0
P2860
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In silico identified CCR4 anta ...... uvant activity in vaccination.
@en
type
label
In silico identified CCR4 anta ...... uvant activity in vaccination.
@en
prefLabel
In silico identified CCR4 anta ...... uvant activity in vaccination.
@en
P2093
P2860
P50
P356
P1476
In silico identified CCR4 anta ...... uvant activity in vaccination.
@en
P2093
Darren R Flower
David F Tough
Emily K Forbes
Matthew N Davies
Michel D Kazatchkine
Peter C L Beverley
Srini V Kaveri
P2860
P304
10221-10226
P356
10.1073/PNAS.0803453105
P407
P577
2008-07-11T00:00:00Z